Last reviewed · How we verify
GM-CSF s.c.
At a glance
| Generic name | GM-CSF s.c. |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection Site Reaction
- Injection site reaction
- Skin Induration
- Fatigue
- Pruritus
- Lymphocyte Count Decreased
- Neutrophil Count Decreased
- White Blood Cell Count Decreased
- SGOT (AST) (serum glutamic oxaloacetic transaminase) (aspartate aminotransferase)
- Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)
- Fatigue (lethargy, malaise, asthenia)
- Hypoalbuminemia
Key clinical trials
- WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (PHASE2)
- WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation (PHASE1, PHASE2)
- GM-CLAG in Relapsed/Refractory FLT3-mutated AML (PHASE1)
- NB2013-HR German (GPOH) / Dutch (DCOG) Trial (PHASE2)
- A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock. (NA)
- GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (PHASE1)
- Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC (PHASE2)
- Sequential Vaccinations in Prostate Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GM-CSF s.c. CI brief — competitive landscape report
- GM-CSF s.c. updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI